Compare Prudential Financial Inc (PRU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs TG Therapeutics Inc — how do they compare? Prudential Financial Inc trades at $113.78 (market cap $39.17B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Prudential Financial Inc is far larger — about 4.8× TG Therapeutics Inc's market cap, and Prudential Financial Inc pays a 4.93% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 145 Days and TG Therapeutics Inc for 16 Days on average.
| PRU | TGTX | |
|---|---|---|
Market Cap | $39.17B | $8.16B |
Volume | 1,436,917 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $125.13 | $59.06 |
52-Week Low | $92.00 | $26.94 |
Typical Hold Time | 145 Days | 16 Days |
Enterprise Value | $67.95B | $8.37B |
Dividend Yield | 4.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $113.09, up 0.65% with bearish technical signals but attractive valuation metrics including a P/E of 10.29 and P/S of 0.61. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. The company is executing a strategic overhaul including $3 billion capital rotation and $750 million cost savings while exiting emerging markets through the $185 million Alexforbes sale. Cash flow trends show strong operational performance with $6.3 billion from operations in 2025.
PRU presents a value opportunity with below-market valuations and dividend yield support, though technical weakness and mixed analyst sentiment warrant caution. The strategic refocus on core insurance and wealth management businesses positions the company for improved capital efficiency, while higher interest rates benefit investment income. Key risks include execution challenges in the restructuring and competitive pressures in the insurance sector.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
